Diabetic kidney disease (DKD) is the most prevalent long-term complication of diabetes, affecting up to 30% of individuals with type 1 diabetes within the first 10 years of diagnosis.
Hirsutism is the excessive hair growth in women in male-typical areas, usually associated with androgen excess and other conditions such as polycystic ovary syndrome (PCOS). The genetic basis of hirsutism remains poorly understood; researchers from the University of Oulu and collaborators performed a meta-analysis of genome-wide association studies from 4,834 cases of hirsutism and 352,966 controls across three cohorts.
Dewpoint Therapeutics Inc. has announced an IND in the U.S. for DPTX-3186, a first-in-class oral condensate modulator designed to selectively disrupt oncogenic Wnt/β-catenin signaling in tumors. Dosing is set to begin before year-end in a phase I/II trial conducted in partnership with cancer centers and opinion leaders in gastric and other Wnt-driven cancers.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadly forms of cancer, with a 5-year relative survival rate of only 13%. To understand cell fate decisions and progression in PDAC, it is crucial to clarify the communication networks between tumor cells.
Durable reprogramming of human T cells may now be possible thanks to a new technique based on the CRISPRoff and CRISPRon methodology. Researchers from the Arc Institute, Gladstone Institutes, and the University of California San Francisco (UCSF) have stably silenced or activated genes in this type of immune cell without cutting or altering its DNA, making T cells more resistant, active, and effective against tumors.
Genescience Pharmaceuticals Co. Ltd. has discovered new tyrosinase (TYR) inhibitors acting as melanin inhibitors potentially useful for the treatment of skin hyperpigmentation.
Alterome Therapeutics Inc. has identified new RAC-α serine/threonine-protein kinase (AKT1; PKB-α) E17K mutant)inhibitors reported to be useful for the treatment of cancer.
Onkure Therapeutics Inc. has disclosed new phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and scoliosis (CLOVES syndrome) and PIK3CA-related overgrowth spectrum.
Excessive signaling by platelet-derived growth factor receptor (PDGFR)-α, a transmembrane tyrosine kinase, helps drive the rapid angiogenesis that many types of tumor cells need in order to proliferate and metastasize.
RSS
